香港股市 將在 1 小時 20 分鐘 開市

MRK Sep 2024 85.000 call

OPR - OPR 延遲價格。貨幣為 USD。
加入追蹤清單
46.880.00 (0.00%)
市場開市。 截至 03:01PM EDT。
全螢幕
前收市價46.88
開市46.88
買盤43.80
賣出價45.50
拍板85.00
到期日2024-09-20
今日波幅46.88 - 46.88
合同範圍
成交量1
未平倉合約7
  • Benzinga

    Covid-19 Pharma Stars Continue Their Quest To Set New Standards In Cancer Treatment

    AstraZeneca PLC (NASDAQ: AZN) kicked off the week by receiving approval from the U.S. Food and Drug Administration for its blockbuster cancer drug Imfinzi combined with chemotherapy being used as a treatment forpatients suffering from specific type of endometrial cancer. Its pharma peer, BioNTech SE (NASDAQ: BNTX) wasn’t as lucky as also on Monday, the FDA put its experimental cancer drug study on partial clinical hold. Combining Immunotherapy And Chemotherapy Is Emerging As A New Standard In Ca

  • Zacks

    Merck's (MRK) 21-Valent Pneumococcal Jab Gets FDA Approval

    Merck's (MRK) 21-valent pneumococcal conjugate vaccine, Capvaxive/V116, becomes the first PCV specifically designed for adults to be approved by the FDA.

  • Insider Monkey

    Is Merck & Co. Inc. (NYSE:MRK) The Best Healthcare Stock to Buy in 2024?

    We recently published a list entitled Billionaire Israel Englander’s Top 10 Stock Picks for 2024. Since Merck & Co. Inc. (NYSE:MRK) ranks 2nd in the list, it deserves a deeper look. Billionaire Israel Englander is one of the most notable hedge fund managers in America. He founded Millennium Management back in 1989. Today, the fund’s portfolio is […]